Study Rationale
State why the trial is needed, the unmet need, the investigational product rationale, and the clinical hypothesis.
Clinical Tools · Protocol Design · ICH M11
Clinical Protocol Synopsis Generator
Build a structured study synopsis outline for clinical trial planning. The generator follows common protocol synopsis sections and reflects ICH M11/CeSHarP concepts for harmonised, reusable protocol content.
Quick Answer
A clinical protocol synopsis is a concise structured summary covering study title, phase, indication, objectives, endpoints, design, population, interventions, sample size, duration, and safety monitoring. ICH M11 CeSHarP places the synopsis near the front of harmonised protocols with objectives mapped to estimands. Pharma teams use synopsis outlines for study planning, cross-functional alignment, and template drafting — then reconcile with the sponsor protocol template and regulatory requirements.
ICH M11 / CeSHarP context
A synopsis should make the protocol logic visible
ICH M11 is intended to harmonise the structure and content of clinical trial protocols through the Clinical electronic Structured Harmonised Protocol model. A strong synopsis is not just an executive summary: it connects the research question, objectives, endpoints, estimands, population, interventions, safety monitoring, and operational design choices.
Interactive Generator
Create a structured protocol synopsis
Enter draft study details below. The preview and plain-text output are generated locally in your browser.
Core Protocol Synopsis Sections
Objectives and Endpoints
Map each objective to an endpoint and timepoint. For confirmatory trials, align the primary objective with the estimand and statistical analysis plan.
Design and Interventions
Describe randomisation, blinding, control, dose groups, visit schedule, treatment duration, and follow-up assumptions.
Population
Summarise target population, key inclusion criteria, key exclusion criteria, stratification factors, and recruitment setting.
Objectives, Endpoints, and Estimands
A synopsis should show how the trial question becomes measurable. The primary objective defines the clinical question, the endpoint defines the measurement, and the estimand clarifies what treatment effect is being estimated. For later-stage studies, unresolved estimand assumptions can create downstream ambiguity in the protocol, statistical analysis plan, and regulatory review.
Define the target population and analysis population.
Specify the endpoint variable, assessment method, and timepoint.
Describe how intercurrent events such as rescue medication, discontinuation, death, or treatment switching will be handled.
Identify the summary measure, such as mean difference, odds ratio, hazard ratio, risk difference, or response proportion.
Inclusion, Exclusion, and Safety Monitoring
Eligibility criteria should protect participants while preserving interpretability and generalisability. In a synopsis, keep criteria high level but explicit enough to reveal major design constraints: disease severity, prior therapy, biomarker status, organ function, pregnancy considerations, prohibited medications, and washout windows.
Safety monitoring should cover adverse event collection, serious adverse event reporting, laboratory assessments, vital signs, ECGs when applicable, dose modification rules, trial stopping criteria, safety review committees, and Data Monitoring Committee oversight when the study risk profile requires it.
Limitations
This generator produces a planning outline, not a compliant protocol. It does not validate regional regulatory requirements, ethics committee expectations, protocol template fields, statistical assumptions, investigational product risk controls, data collection standards, or operational feasibility.
Final protocol content should be reviewed by clinical development, biostatistics, pharmacovigilance, regulatory affairs, data management, medical writing, and trial operations teams.
Pharma & clinical trial context
Protocol synopsis drafting is an early cross-functional milestone — clinical development, biostatistics, regulatory affairs, pharmacovigilance, and medical writing align on objectives, endpoints, estimands, and design before full protocol authoring. ICH M11 CeSHarP and TransCelerate CPT V011 both place synopsis content near the front of harmonised protocols for investigator and regulator readability.
Use this generator for planning workshops and template pre-population, then migrate content into the sponsor CeSHarP or CPT Word template. Pair with the Visit Schedule Builder for SoA timing, the Sample Size Calculator for power assumptions, and ICH Guidelines reference for E6, E9(R1), and M11 cross-walks.
Evidence & sources
- ICH M11 clinical electronic Structured Harmonised Protocol guidance and template materials
- European Medicines Agency clinical trials guidance and protocol template resources
- ClinicalTrials.gov study design and clinical study basics
- Competitive landscape: TransCelerate Common Protocol Template V011 is the industry-standard Word template aligned with ICH M11 — download-and-author, not an interactive browser generator with live preview. ICH M11 CeSHarP Template (EMA) is the regulatory authority synopsis structure — PDF/Word authoring without fill-and-export workflow. NovaPharmaNews provides a free interactive synopsis outline with estimand checklist and plain-text copy — no login.
Frequently Asked Questions
What is a clinical protocol synopsis?
A clinical protocol synopsis is a concise structured summary of the protocol. It usually covers the study title, phase, indication, objectives, endpoints, design, population, interventions, sample size, duration, safety monitoring, and key eligibility criteria.
How does ICH M11 relate to protocol synopsis writing?
ICH M11 introduces a harmonised clinical electronic Structured Harmonised Protocol, often called CeSHarP, to make protocol content more consistent, digital, and reusable across sponsors, investigators, regulators, and ethics committees. The synopsis appears in Section 1.1 with objectives, estimands, and overall design.
What does CeSHarP require in the protocol synopsis?
CeSHarP Section 1.1 expects a brief summary of primary and secondary objectives, associated estimands in layperson language, overall design, and schema references. Cross-references to detailed sections are acceptable to keep the synopsis concise while maintaining traceability.
Should objectives, endpoints, and estimands be aligned?
Yes. Each primary objective should map to a primary endpoint and, where relevant, an estimand that defines the treatment condition, population, endpoint variable, intercurrent event strategy, and summary measure per ICH E9(R1).
How is a synopsis different from TransCelerate CPT?
TransCelerate Common Protocol Template (CPT V011) is a Word-based industry template aligned with ICH M11 for full protocol authoring. This browser generator produces a planning outline with plain-text export — useful before populating the sponsor CPT or CeSHarP template.
Can this generator replace a sponsor protocol template?
No. This page creates a planning synopsis only. Final protocols should follow the sponsor template, ICH M11 guidance, regional regulatory requirements, statistical input, safety input, and ethics committee expectations.
What should safety monitoring include in a synopsis?
Safety monitoring should describe adverse event collection, serious adverse event reporting, laboratory or clinical assessments, stopping rules if applicable, and any Data Monitoring Committee or safety review cadence.
How should secondary endpoints be formatted in a synopsis?
List secondary endpoints with endpoint variable, timepoint, and assessment method — one per line for clarity. Map each to a secondary objective where applicable. Detailed statistical methods belong in the statistical analysis plan, not the synopsis.
What intercurrent events should the estimand checklist cover?
Common intercurrent events include rescue medication, treatment discontinuation, death, treatment switching, and protocol deviations affecting endpoint interpretation. The synopsis should note how each primary endpoint handles these events per ICH E9(R1) before protocol finalisation.
Can I copy the generated synopsis into my sponsor template?
Yes. Use the plain-text export and structured preview as a drafting starting point. Paste into the sponsor Word or CeSHarP template, then refine with clinical development, biostatistics, regulatory affairs, pharmacovigilance, and medical writing review.
How does this relate to the visit schedule builder?
The synopsis describes overall design, duration, and visit schedule assumptions at a high level. Use the Visit Schedule Builder to calculate anchor-date visit windows and CSV exports once SoA timing rules are defined.
Does this tool validate regulatory compliance?
No. This generator produces a planning outline only. It does not validate regional regulatory requirements, ethics committee expectations, investigational product risk controls, or operational feasibility. Final content requires multidisciplinary review.